Exosome Development and Manufacturing Services Market by Scale of Operation (Discovery / Research, Preclinical and Clinical) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    February 2022

  • Pages
    215

  • View Count
    1482

Example Insights

Exosome-Development-and-Manufacturing-Services-Market-Context Exosome-Development-and-Manufacturing-Services-Market-Service-Providers Exosome-Development-and-Manufacturing-Services-Market-Year-of-Establishment Exosome-Development-and-Manufacturing-Services-Market-Competitiveness-Analysis
Exosome-Development-and-Manufacturing-Services-Market-Type-of-Partnership Exosome-Development-and-Manufacturing-Services-Market-Publication-Analysis Exosome-Development-and-Manufacturing-Services-Market-Event-Analysis Exosome-Development-and-Manufacturing-Services-Market-Technology-Providers
Exosome-Development-and-Manufacturing-Services-Market-Patent-Analysis Exosome-Development-and-Manufacturing-Services-Market-Trial-Analysis Exosome-Development-and-Manufacturing-Services-Market-Scale-of-Operation  

 

Overview

Our technology has the potential to produce extracellular vesicles at high yield and is beneficial for large scale manufacturing of exosomes required for producing therapeutics. Moreover, some exosome based therapeutic developers have also licensed our technology platform with an aim to produce exosomes and develop breakthrough biotherapies

-- Chief Compliance Officer and Co-Founder, Switzerland-based small-sized firm

Exosomes are extracellular vesicles that play an important role in cell-to-cell communication and act as carriers of circulating nucleic acids, lipids and proteins in body. Over time, various research studies have demonstrated the potential of exosomes in disease diagnosis and drug delivery applications, owing to their ability to act as biomarkers for various diseases and transport important functional elements. Given the various benefits, exosomes have gained significant interest in the biopharmaceutical industry, likely to result in their increased demand. However, the development and manufacturing of exosomes is associated with several challenges, including lack of standardized isolation and purification methods, limited drug loading ability, and inadequate clinical grade production and GMP compliant industrial scale-up. Therefore, outsourcing of exosome development and manufacturing is seen as a preferable option by companies focused on development of exosome based diagnostics and therapeutics.

Presently, several companies offer services for exosome development and manufacturing. The primary benefit of engaging service providers is to overcome various challenges related to exosome development, such as heterogeneity of exosomes, optimization of exosome isolation, purification and characterization methods and lack of specific biomarkers. Further, in order to leverage the full potential of exosomes, advanced exosome technologies are being developed to fully substructure their therapeutic applications. In addition, extensive research is being conducted to develop methods for extraction of exosomes with high level of purity and sensitivity. The growth in research over the last few years is evident from the published scientific literature and the clinical trial activity in this domain. The market has also witnessed substantial partnership activity, including several technology licensing deals. Moreover, the service providers are actively upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for these extracellular vesicles. Driven by the ongoing research activity, technological advancements and efforts of the players offering exosome development and manufacturing services, the market is poised to witness healthy growth over the next decade.

Scope of the Report

The “Exosome Development and Manufacturing Services Market by Scale of Operation (Discovery / Research, Preclinical and Clinical) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely future potential of exosome service providers over the next decade. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this field. In addition to other elements, the report includes:

  • A detailed assessment of the current market landscape of exosome service providers along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).
  • A competitiveness analysis of exosome service providers based on various relevant parameters, such as supplier strength (based on the experience / expertise of the service providers and company size), service strength (number of stages of development (discovery, preclinical, clinical or commercialized), scalability criteria, number of isolation and purification methods, number of characterization methods, number of chromatography techniques, quality control methods and exosome manufacturing methods).
  • Detailed profiles of prominent exosome service providers. Each company profile features a brief overview of the company, its financial information (if available), details on its exosome service portfolio, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been established in this domain since 2016, covering R&D agreements, research, development and commercialization collaborations, product development agreements, mergers and acquisitions, product development and commercialization agreements, distribution / supply agreements, licensing deals, asset acquisitions, and clinical trial agreements. 
  • A detailed review of 6,451 peer-reviewed, scientific articles related to research on exosomes on the basis of several relevant parameters, such as year of publication, type of service(s) offered, emerging focus areas. The chapter also highlights the top journals (in terms of number of articles published and impact factor).
  • A detailed analysis of the global events attended by the participants, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events). The chapter also highlights the geographical mapping of upcoming events.
  • An overview of the landscape of exosome-based technologies, featuring analyses of various technology providers, based on several relevant parameters, such as year of establishment, company size and location of headquarters.
  • An insightful analysis of the patents filed / granted for exosome technologies, during the period between 2016 and 2021 (till November), taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus areas, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent benchmarking, patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.
  • A detailed analysis of completed and ongoing clinical trials of exosomes, based on different parameters, such as trial status, trial registration year, trial registration year and enrolled patient population, trial recruitment status, trial phase and number of patients enrolled, study design, type pf sponsor / collaborator, leading players (on basis of number of registered trials),emerging focus areas and location of the trials (on basis of number of registered trials and enrolled patient population).

One of the key objectives of the report was to evaluate the existing market size, primary growth factors and opportunity within the exosome development and manufacturing services market in the mid to long term. Our year-wise projections of the current and future opportunity within the exosome development and manufacturing services market have further been segmented across [A] scale of operation (discovery / pre-clinical stage and clinical stage) [B] key geographies (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the anticipated industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Jonathan Carson (Strategic Marketing Manager, RoosterBio)
  • Navdeep Singh (Product Manager and Technical Lead, Clara Biotech)
  • Nicolas Rousseau (Chief Compliance Officer and Co-founder, EverZom)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players offering exosome related services?
  • Which are the various technology platforms available in the market for the development of exosomes?
  • What is the relative competitiveness of different exosome service providers?
  • What kind of partnership models are commonly adopted by industry and non-industry stakeholders?
  • What is the focus area of the ongoing research activities related to exosomes?
  • How has the intellectual property landscape of exosomes evolved over the years?
  • What are the key agenda items being discussed in various global events / conferences related to exosomes?
  • Which companies are actively involved in conducting clinical trials for exosomes?
  • How is the current and future market opportunity related to exosomes, likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the current status of exosome development and manufacturing services market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to exosomes, types of extracellular vesicles and composition of exosomes. Further, the chapter presents details on the various therapeutic applications of exosomes, advantages and challenges associated with the development and manufacturing of exosomes along with the future perspectives. In addition, the chapter provides information on the isolation, characterization, manufacturing and outsourcing of exosome related services.

Chapter 4 includes information on more than 45 exosome service providers that are currently offering services related to exosomes, and a detailed analysis based on several parameters, such as types of service(s) offered, method of isolation, method of purification, method of characterization, method of exosome manufacturing, scale of operation and scalability. In addition, it provides details on the companies along with information on their year of establishment, company size and location of headquarters.

Chapter 5 provides a competitiveness analysis of exosomes service providers based on various relevant parameters, such as supplier strength (based on the experience / expertise of the service providers and company size), service strength (number of stages of development, scalability criteria, number of isolation and purification methods, number of characterization methods, number of chromatography techniques, quality control methods and exosome manufacturing methods).

Chapter 6 includes detailed profiles of prominent players offering exosome related services. Each profile features a brief overview of the company, its financial information (if available), details on its exosome service portfolio, recent developments and an informed future outlook.

Chapter 7 features an insightful analysis of the partnerships that have been established in this domain, during the period between 2016 and 2021 (till November)., covering R&D agreements, research, development and commercialization collaborations, product development agreements, mergers and acquisitions, product development and commercialization agreements, distribution / supply agreements, licensing deals, asset acquisitions, and clinical trial agreements. 

Chapter 8 features a detailed review of peer-reviewed, scientific articles related to research on exosomes, on the basis of several relevant parameters, such as year of publication, type of service(s) offered, emerging focus areas. The chapter also highlights the top journals (in terms of number of articles published and impact factor).

Chapter 9 features an analysis of the global events attended by the service providers, based on several parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events). The chapter also highlights the geographical mapping of upcoming events.

Chapter 10 presents an overview of the landscape of exosome-based technologies, featuring analyses of various technology providers, based on several relevant parameters, such as year of establishment, company size and location of headquarters.

Chapter 11 provides an insightful analysis of the patents filed / granted for exosomes during the period between 2016 and 2021 (till November) taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus area, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent benchmarking, patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.

Chapter 12 provides information on completed and ongoing clinical studies of exosomes, based on different parameters, such as trial status, trial registration year, trial registration year and enrolled patient population, trial recruitment status, trial phase and number of patients enrolled, study design, type pf sponsor / collaborator, leading players (on basis of number of registered trials), emerging focus areas and  location of the trials (on basis of number of registered trials and enrolled patient population).

Chapter 13 features an insightful market forecast analysis, highlighting the likely growth of the exosome development and manufacturing services market, till the year 2035. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] scale of operation (discovery / pre-clinical stage and clinical stage) [B] key geographies (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 14 summarizes the entire report, highlighting various facts related to contemporary market trend and the likely evolution of the exosome development and manufacturing services market. 

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. In this chapter, we have presented detailed transcripts of interviews held with (in alphabetical order) Jonathan Carson (Strategic Marketing Manager, RoosterBio), Navdeep Singh (Product Manager and Technical Lead, Clara Biotech) and Nicolas Rousseau (Chief Compliance Officer and Co-founder, EVerZom).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Extracellular Vesicles
3.2.1. Apoptotic bodies: An Overview
3.2.2. Micro vesicles: An Overview
3.2.3. Exosomes: An Overview
3.3. Composition of Exosomes
3.4. Exosome Biogenesis
3.5 Exosome Development: An Overview
3.5.1. Methods for Isolation of Exosomes
3.5.2. Methods for Purification of Exosomes
3.5.3. Methods for Characterization of Exosomes
3.6. Manufacturing of Exosomes
3.7. Outsourcing of Exosomes related Services
3.8. Therapeutic Applications of Exosomes
3.8.1. Modification of Immune System
3.8.2. Exosomes as Targeted Drug Delivery Vehicles
3.8.3. Engineered Exosomes
3.9. Challenges Associated with the Development and Manufacturing of Exosomes
3.9.1. Lack of Standardized Isolation and Purification Methods
3.9.2. Limited Drug Loading Ability
3.9.3. Inadequate Clinical Grade Production
3.10. Future Perspectives

4. EXOSOME SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Exosome Service Providers: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Headquarters and Company Size
4.3. Analysis by Type of Service(s) Offered
4.3.1. Analysis by Method of Isolation
4.3.2. Analysis by Method of Purification
4.3.3. Analysis by Method of Characterization
4.3.4. Analysis by Method of Exosome Manufacturing
4.3.5. Analysis by Scale of Operation
4.3.6. Analysis by Scalability

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Scope and Methodology
5.4. Company Competitiveness Analysis: Exosome Service Providers in North America
5.5. Company Competitiveness Analysis: Exosome Service Providers in Europe
5.6. Company Competitiveness Analysis: Exosome Service Providers in Asia-Pacific and Rest of the World

6. COMPANY PROFILES: EXOSOME SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Creative Bioarray
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook

6.2.2 Creative Biolabs
6.2.2.1 Company Overview
6.2.2.2 Service Portfolio
6.2.2.3 Recent Developments and Future Outlook

6.2.3. Creative Biostructure
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook

6.3. Key Players based in Europe
6.3.1. Amsbio
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. Cambridge Bioscience
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Recent Developments and Future Outlook

6.3.3. Lonza
6.3.3.1 Company Overview
6.3.3.2. Financial Information
6.3.3.3. Service Portfolio
6.3.3.4. Manufacturing Facilities
6.3.3.5. Recent Developments and Future Outlook

6.3.4. Qiagen
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Recent Developments and Future Outlook

6.4. Key Players based in Asia-Pacific
6.4.1. Exopharm
6.4.1.1. Company Overview
6.4.1.2. Financial Information
6.4.1.3. Service Portfolio
6.4.1.4. Recent Developments and Future Outlook

6.4.2. Sumika Chemical Analysis Service
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Exosome Service Providers: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Type of Service Offered
7.3.6. Word Cloud Analysis: Emerging Focus Areas
7.3.7. Analysis by Target Disease Indication
7.3.8. Analysis by Therapeutic Area
7.3.9. Analysis by Type of Technology
7.3.10. Most Active Players: Analysis by Number of Partnerships
7.3.11. Analysis by Type of Service Offered and Type of Partnership
7.3.12. Analysis by Target Disease Indication and Type of Partnership
7.3.13. Regional Analysis
7.3.14. Intercontinental and Intracontinental Agreements

8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Service Offered
8.2.3. Word Cloud Analysis: Emerging Focus Areas
8.2.4. Popular Journals: Analysis by Number of Publications
8.2.5. Popular Journals: Analysis by Journal Impact Factor

9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Location of Event
9.3.5. Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area
9.3.6. Most Active Organizers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Most Active Speakers: Analysis by Number of Events
9.3.12. Geographical Mapping of Upcoming Events

10. EXOSOME BASED TECHNOLOGIES: MARKET OVERVIEW
10.1. Chapter Overview
10.2. Exosome Technologies: An Overview
10.3. List of Exosome Technology Providers
10.3.1. Exosome Technology Providers: Analysis by Year of Establishment
10.3.2. Exosome Technology Providers: Analysis by Company Size
10.3.3. Exosome Technology Providers: Analysis by Location of Headquarters
10.4 Exosome Technologies: Information of Technology Related Services and Therapeutic Applications
10.4.1 Summary

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Exosomes Technologies: Patent Analysis
11.3.1. Analysis by Type of Patent
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Application Year
11.3.4. Analysis by Geographical Location
11.3.5. Analysis by CPC Symbols
11.3.6. Word Cloud Analysis: Emerging Focus Areas
11.3.7. Analysis Type of Organization
11.3.8. Leading Industry Players: Analysis by Number of Patents
11.3.9. Leading Non-Industry Players: Analysis by Number of Patents
11.3.10. Leading Patent Assignees: Analysis by Number of Patents
11.4. Exosome Technologies: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics (CPC Symbols)
11.5 Analysis of Patents by Age
11.6. Patent Valuation Analysis
11.7. Leading Patents by Number of Citations

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Analysis by Trial Status
12.4. Analysis by Trial Registration Year
12.5. Analysis by Trial Registration Year and Enrolled Patient Population
12.6. Analysis by Trial Recruitment Status
12.7. Analysis by Trial Phase and Number of Patients Enrolled
12.8. Analysis by Study Design
12.9. Analysis by Type of Sponsor / Collaborator
12.10. Leading Players: Analysis by Number of Registered Trials
12.11. Word Cloud Analysis: Emerging Focus Areas
12.12. Geographical Analysis by Number of Registered Trails
12.13. Geographical Analysis by Enrolled Patient Population

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Exosome Development and Manufacturing Services: Technology Licensing Model
13.4. Global Exosome Development and Manufacturing Services Market, 2022-2035
13.4.1. Global Exosome Development and Manufacturing Services Market: Distribution by Stage of Application, 2022 and 2035
13.4.1.1. Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical Stage
13.4.1.2. Global Exosome Development and Manufacturing Services Market for Clinical Stage
13.4.3. Global Exosome Development and Manufacturing Services Market: Distribution by Region, 2022 and 2035
13.4.3.1. Exosome Development and Manufacturing Services Market in North America, 2022-2035
13.4.3.2. Exosome Development and Manufacturing Services Market in Europe, 2022-2035
13.4.3.3. Exosome Development and Manufacturing Services Market in Asia Pacific, 2022-2035
13.4.3.4. Exosome Development and Manufacturing Services Market in Rest of the World, 2022-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. EVerZom
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nicolas Rousseau, Chief Compliance Officer and Cofounder
15.3. Clara Biotech
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Navdeep Singh, Product Manager and Technical Lead
15.4. RoosterBio
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Jonathan Carson, Strategic Marketing Manager

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Forecast
Figure 2.2 Executive Summary: Overall Market Landscape of Exosome Development and Manufacturing Services
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Global Events
Figure 2.6 Executive Summary: Overall Market Landscape of Exosomes Technologies
Figure 2.7 Executive Summary: Patent Analysis
Figure 2.8 Executive Summary: Clinical Trial Analysis
Figure 3.1 Exosome Biogenesis
Figure 3.2 Methods for Isolation of Exosomes
Figure 3.3 Methods for Purification of Exosomes
Figure 3.4 Methods for Characterization of Exosomes
Figure 4.1 Exosome Service Providers: Distribution by Year of Establishment
Figure 4.2 Exosome Service Providers: Distribution by Company Size
Figure 4.3 Exosome Service Providers: Distribution by Location of Headquarters
Figure 4.4 Exosome Service Providers: Distribution by Location of Headquarters and Company Size
Figure 4.5 Exosome Service Providers: Distribution by Type of Service(s) Offered
Figure 4.6 Exosome Service Providers: Distribution by Method(s) of Isolation
Figure 4.7 Exosome Service Providers: Distribution by Method(s) of Purification
Figure 4.8 Exosome Service Providers: Distribution by Method(s) of Characterization
Figure 4.9 Exosome Service Providers: Distribution by Method(s) of Exosome Manufacturing
Figure 4.10 Exosome Service Providers: Distribution by Scale of Operation
Figure 4.11 Exosome Service Providers: Distribution by Scalability
Figure 5.1 Company Competitiveness Analysis: Exosome Service Providers in North America
Figure 5.2 Company Competitiveness Analysis: Exosome Service Providers in Europe
Figure 5.3 Company Competitiveness Analysis: Exosome Service Providers in Asia-Pacific and Rest of the World
Figure 6.1 Lonza: Annual Revenues, 2016-Q2 2021 (CHF Billion)
Figure 6.2 Qiagen: Annual Revenues, 2016-Q3 2021 (CHF Billion)
Figure 6.3 Exopharm: Annual Revenues, 2018- Q2 2021 (CHF Million)
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2021 (till November)
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2016-2021 (till November)
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Service Offered
Figure 7.6 Word Cloud Analysis: Emerging Focus Areas
Figure 7.7 Partnerships and Collaborations: Distribution by Disease Indication
Figure 7.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.9 Partnerships and Collaborations: Distribution by Type of Technology
Figure 7.10 Most Active Players: Distribution by Number of Partnerships
Figure 7.11 Partnerships and Collaborations: Distribution by Type of Service Offered and Type of Partnership
Figure 7.12 Partnerships and Collaborations: Distribution by Disease Indication and Type of Partnership
Figure 7.13 Partnerships and Collaborations: Regional Distribution
Figure 7.14 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2021 (till November)
Figure 8.2 Publication Analysis: Distribution by Type of Service Offered
Figure 8.3 Publication Analysis: Word Cloud of Study Titles
Figure 8.4 Popular Journals: Distribution by Number of Publications
Figure 8.5 Popular Journals: Distribution by Journal Impact Factor
Figure 9.1 Global Events: Cumulative Half Yearly Trend, H1 2017-H2 2021
Figure 9.2 Global Events: Distribution by Event Platform
Figure 9.3 Global Events: Distribution by Type of Event
Figure 9.4 Global Events: Distribution by Location of Event
Figure 9.5 Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area
Figure 9.6 Most Active Organizers: Distribution by Number of Events
Figure 9.7 Most Active Industry Participants: Distribution by Number of Events
Figure 9.8 Most Active Non-Industry Participants: Distribution by Number of Events
Figure 9.9 Global Events: Distribution by Designation of Participant
Figure 9.10 Global Events: Distribution by Affiliated Department of Participant
Figure 9.11 Most Active Speakers: Distribution by Number of Events
Figure 9.12 Global Events: Geographical Mapping of Upcoming Events
Figure 10.1 Exosome Technology Providers: Distribution by Year of Establishment
Figure 10.2 Exosome Technology Providers: Distribution by Company Size
Figure 10.3 Exosome Technology Providers: Distribution by Location of Headquarters
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year, 2011-2021 (till November)
Figure 11.3 Patent Analysis: Cumulative Distribution by Application Year, Pre-2016-2021 (till November)
Figure 11.4 Patent Analysis: Distribution by Geographical Location
Figure 11.5 Patent Analysis: Distribution by CPC Symbols
Figure 11.6 Word Cloud: Emerging Focus Areas
Figure 11.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 11.8 Leading Industry Players: Distribution by Number of Patents
Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10 Patent Analysis: Leading Individual Assignees
Figure 11.11 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics (CPC Symbols)
Figure 11.12 Patent Analysis: Distribution of Patents by Age (2001-2020)
Figure 11.13 Exosome Technologies: Patent Valuation Analysis
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2021
Figure 12.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2016-2021
Figure 12.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 12.6 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Figure 12.7 Clinical Trial Analysis: Distribution by Study Design
Figure 12.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.9 Leading Players: Distribution by Number of Registered Trials
Figure 12.10 Word Cloud: Emerging Focus Areas
Figure 12.11 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 12.12 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Exosomes Technologies: Information on Licensing Deals
Figure 13.3 Global Exosome Development and Manufacturing Services Market, 2022-2035
Figure 13.3 Global Exosome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
Figure 13.4 Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical Stage
Figure 13.5 Global Exosome Development and Manufacturing Services Market for Clinical Stage
Figure 13.6 Global Exosome Development and Manufacturing Services Market: Distribution by Region, 2022 and 2035
Figure 13.7 Exosome Development and Manufacturing Services Market in North America, 2022-2035
Figure 13.8 Exosome Development and Manufacturing Services Market in Europe, 2022-2035
Figure 13.9 Exosome Development and Manufacturing Services Market in Asia Pacific, 2022-2035
Figure 13.10 Exosome Development and Manufacturing Services Market in Rest of the World, 2022-2035
Figure 14.1 Concluding Remarks: Market Landscape of Exosome Development and Manufacturing Services
Figure 14.2 Concluding Remarks: Company Competitiveness Analysis
Figure 14.3 Concluding Remarks: Partnership and Collaborations
Figure 14.4 Concluding Remarks: Publication Analysis
Figure 14.5 Concluding Remarks: Global Event Analysis
Figure 14.6 Concluding Remarks: Market Landscape of Exosome Technology Providers
Figure 14.7 Concluding Remarks: Patent Analysis
Figure 14.8 Concluding Remarks: Clinical Trial Analysis
Figure 14.9 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Protein Family of Exosomes
Table 4.1 Exosome Service Providers: List of Industry Players
Table 4.2 Exosome Service Providers: Information on Type of Service(s) Offered
Table 4.3 Exosome Service Providers: Information on Method(s) of Isolation
Table 4.4 Exosome Service Providers: Information on Method(s) of Purification
Table 4.5 Exosome Service Providers: Information on Method(s) of Characterization
Table 4.6 Exosome Service Providers: Information on Method(s) of Exosome Manufacturing
Table 4.7 Exosome Service Providers: Information on Scale of Operation
Table 4.8 Exosome Service Providers: Information on Scalability
Table 6.1 Exosome Service Providers: List of Companies Profiled
Table 6.2 Creative Bioarray: Company Snapshot
Table 6.3 Creative Bioarray: Recent Developments and Future Outlook
Table 6.4 Creative Biolabs: Company Snapshot
Table 6.5 Creative Biolabs: Recent Developments and Future Outlook
Table 6.6 Creative Biostructure: Company Snapshot
Table 6.7 Creative Biostructure: Recent Developments and Future Outlook
Table 6.8 Amsbio: Company Snapshot
Table 6.9 Amsbio: Recent Developments and Future Outlook
Table 6.10 Cambridge Biosciences: Company Snapshot
Table 6.11 Cambridge Biosciences: Recent Developments and Future Outlook
Table 6.12 Lonza: Company Snapshot
Table 6.13 Lonza: Information on Manufacturing Facilities
Table 6.14 Lonza: Recent Developments and Future Outlook
Table 6.15 Qiagen: Company Snapshot
Table 6.16 Qiagen: Recent Developments and Future Outlook
Table 6.17 Exopharm: Company Snapshot
Table 6.18 Exopharm: Recent Developments and Future Outlook
Table 6.19 Sumika Chemical Analysis Service: Company Snapshot
Table 7.1 Exosome Service Providers: List of Partnerships and Collaborations, 2016-2021 (till November)
Table 9.1 List of Global Events related to Exosomes
Table 10.1 Exosome Technology Providers: Information on Technology Platforms
Table 10.2 Technology Providers: Information on Technology Related Services and Therapeutic Applications
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: List of Top CPC Symbols
Table 11.3 Patent Analysis: Most Popular CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 15.1 Rooster Bio: Key Highlights
Table 16.1 Exosome Service Providers: Distribution by Year of Establishment
Table 16.2 Exosome Service Providers: Distribution by Company Size
Table 16.3 Exosome Service Providers: Distribution by Location of Headquarters
Table 16.4 Exosome Service Providers: Distribution by Location of Headquarters and Company Size
Table 16.5 Exosome Service Providers: Distribution by Type of Services Offered
Table 16.6 Exosome Service Providers: Distribution by Method(s) of Isolation
Table 16.7 Exosome Service Providers: Distribution by Method(s) of Purification
Table 16.8 Exosome Service Providers: Distribution by Method(s) of Characterization
Table 16.9 Exosome Service Providers: Distribution by Method(s) of Exosome Manufacturing
Table 16.10 Exosome Service Providers: Distribution by Scale of Operation
Table 16.11 Exosome Service Providers: Distribution by Scalability
Table 16.12 Lonza: Annual Revenues, 2016-H1 2021 (CHF Billion)
Table 16.13 Qiagen: Annual Revenues, 2016-9M 2021 (CHF Billion)
Table 16.14 Exopharm: Annual Revenues, 2018- 2021 (CHF Million)
Table 16.15 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2021 (till November)
Table 16.16 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.17 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2016-2021 (till November)
Table 16.18 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.19 Partnerships and Collaborations: Distribution by Type of Service
Table 16.20 Partnerships and Collaborations: Distribution by Type of Disease Indication(s)
Table 16.21 Partnerships and Collaborations: Distribution by Type of Therapeutic Area
Table 16.22 Partnerships and Collaborations: Distribution by Type of Technology
Table 16.23 Most Active Players: Distribution by Number of Partnerships
Table 16.24 Partnerships and Collaborations: Distribution by Type of Service and Type of Partnership
Table 16.25 Partnerships and Collaborations: Distribution by Disease Indication and Type of Partnership
Table 16.26 Partnerships and Collaborations: Regional Distribution
Table 16.27 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.28 Publication Analysis: Cumulative Year-wise Trend, 2017-2021 (till November)
Table 16.29 Publication Analysis: Distribution by Type of Service Offered
Table 16.30 Popular Journals: Distribution by Number of Publications
Table 16.31 Popular Journals: Distribution by Journal Impact Factor
Table 16.32 Global Events: Cumulative Half Yearly Trend, H1 2017-H2 2021
Table 16.33 Global Events: Distribution by Event Platform
Table 16.34 Global Events: Distribution by Type of Event
Table 16.35 Global Events: Distribution by Location of Event
Table 16.36 Global Events: Distribution by Event Organizers
Table 16.37 Most Active Industry Participants: Distribution by Number of Events
Table 16.38 Most Active Non-Industry Participants: Distribution by Number of Events
Table 16.39 Global Events: Distribution by Designation of Participant
Table 16.40 Global Events: Distribution by Affiliated Department of Participant
Table 16.41 Most Active Speakers: Distribution by Number of Events
Table 16.42 Technology Providers: Distribution of Developers by Year of Establishment
Table 16.43 Technology Providers: Distribution of Developers by Company Size
Table 16.44 Technology Providers: Distribution of Developers by Region
Table 16.45 Patent Analysis: Distribution by Type of Patent
Table 16.46 Patent Analysis: Cumulative Distribution by Publication Year, 2011-2021 (till November)
Table 16.47 Patent Analysis: Cumulative Distribution by Application Year, Pre-2016-2021
Table 16.48 Patent Analysis: Distribution by Geographical Location
Table 16.49 Patent Analysis: Distribution by CPC Symbols
Table 16.50 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Table 16.51 Leading Industry Players: Distribution by Number of Patents
Table 16.52 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.53 Patent Analysis: Leading Individual Assignees
Table 16.54 Patent Analysis: Distribution of Patents by Age (2001-2020)
Table 16.55 Exosome Technologies: Patent Valuation Analysis
Table 16.56 Clinical Trial Analysis: Distribution by Trial Status
Table 16.57 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2021
Table 16.58 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2016-2021
Table 16.59 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Table 16.60 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Table 16.61 Clinical Trial Analysis: Distribution by Study Design
Table 16.62 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.63 Most Active Players: Distribution by Number of Registered Trials
Table 16.64 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 16.65 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 16.66 Licensing Agreements: Distribution of Financial Components
Table 16.67 Exosomes Technologies: Information on Licensing Deals
Table 16.68 Global Exosome Development and Manufacturing Services Market, 2022-2035
Table 16.69 Global Exosome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
Table 16.70 Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical Stage
Table 16.71 Global Exosome Development and Manufacturing Services Market for Clinical Stage
Table 16.72 Global Exosome Development and Manufacturing Services Market: Distribution by Region, Conservative, Base and Optimistic Scenarios, 2022 and 2035
Table 16.73 Exosome Development and Manufacturing Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035
Table 16.74 Exosome Development and Manufacturing Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035
Table 16.75 Exosome Development and Manufacturing Services Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035
Table 16.76 Exosome Development and Manufacturing Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 101 Bio
  2. 10x Genomics
  3. Aegle Therapeutics
  4. Aethlon Medical 
  5. AlfatestLab
  6. American Association for the Advancement of Science (AAAS)
  7. American Society for Bone and Mineral Research (ASBMR)
  8. Amgen
  9. AMSBIO
  10. Anjarium Biosciences
  11. Anopoli Biomedical Systems
  12. Aruna Bio
  13. ASN Events
  14. Beth Israel Deaconess Medical Center
  15. BioCat
  16. BioPharma Asia
  17. Biosyyd
  18. BioTech Pharma Summit
  19. Bio-Techne
  20. BioXpedia
  21. Broad Institute of MIT and Harvard
  22. Cambridge Bioscience
  23. Capital Biosciences 
  24. Capricor Therapeutics
  25. CD Bioparticles
  26. Cell Guidance Systems
  27. Cellex 
  28. Cellular Biomedicine Group (CBMG)
  29. Center for Biologics Evaluation and Research (CBER)
  30. CHA Biotech
  31. Ciloa 
  32. Clara Biotech
  33. Codiak BioSciences
  34. Craif
  35. Creative Bioarray
  36. Creative Biolabs
  37. Creative Biostructure
  38. Creative Proteomics
  39. Curexsys
  40. David H. Murdock Research Institute (DHMRI)
  41. Direct Biologics
  42. Editas Medicine
  43. EriVan Bio
  44. European Society of Cardiology (ESC)
  45. Esco Aster
  46. EV Therapeutics 
  47. Evercyte
  48. EVerZom
  49. Evox Therapeutics
  50. Excilone
  51. Excipio Technologies
  52. EXIT071
  53. ExoCoBio
  54. Exogenus Therapeutics
  55. Exolitus
  56. ExoModTech
  57. Exopharm
  58. Exosome Diagnostics
  59. Exosome Sciences (Acquired by Aethlon Medical)
  60. Exosome Plus
  61. Exosomics
  62. ExoVectory
  63. Finnish Red Cross
  64. Florica Therapeutics
  65. Frontage Laboratories
  66. Fusion Conferences
  67. GeneCopoeia
  68. George Mason University
  69. Goodwin Biotechnology
  70. HansaBioMed Life Sciences (Acquired by Lonza)
  71. Hanson Wade
  72. Harvard University
  73. Henry Ford Health System
  74. ILIAS Biologics 
  75. Immunostep
  76. Innovex Therapeutics
  77. Inscripta
  78. Intezyne Technologies
  79. Italian Association of Cell Culture (AICC)
  80. Izasa Scientific
  81. Izon Science
  82. Jazz Pharmaceuticals
  83. Kimera Labs
  84. Lifeasible
  85. Lonza
  86. Luminous BioSciences 
  87. Macrogen
  88. Mahe Technologies
  89. Mantra Bio
  90. Marin Biologic Laboratories
  91. Massachusetts General Hospital
  92. Massachusetts Institute of Technology
  93. MDimune
  94. Merck
  95. Miltenyi Biotec
  96. Moderna
  97. Nanovex Biotechnologies 
  98. NanoView Biosciences
  99. National Cancer Institute (NCI)
  100. National Institute for Health and Medical Research (INSERM) (Acquired by Inserm Transfert)
  101. National Taiwan University Hospital
  102. NeuroDex
  103. Norgen Biotek
  104. Novus Biologicals (Acquired by Bio-Techne)
  105. NurExone Biologic
  106. Ocean Ridge Biosciences
  107. Omnigene Medical technologies
  108. OmniSpirant
  109. OPTOLANE Technologies
  110. Organicell Regenerative Medicine
  111. Pathways to Stem Cell Science
  112. Progenity
  113. QIAGEN
  114. Quantum Design
  115. Ragon Institute of MGH, MIT and Harvard
  116. Regeneron Pharmaceuticals
  117. ReNeuron
  118. RoosterBio
  119. Ruijin Hospital
  120. Sanford Burnham Prebys Medical Discovery Institute
  121. Sarepta Therapeutics
  122. System Biosciences (SBI)
  123. SelectBIO
  124. SMi Group
  125. Spectradyne
  126. Stanford University
  127. Sumika Chemical Analysis Service
  128. System Biosciences
  129. Takeda
  130. The Cell Factory 
  131. University Medical Center Utrecht
  132. University of Texas
  133. Thermo Fisher Scientific
  134. Thomas Jefferson University
  135. Toray Industries
  136. Tymora Analytical Operations
  137. UCL Translational Research Office 
  138. uFluidix
  139. University Hospital Bonn (UKB)
  140. Unicyte
  141. University of California
  142. University of Paris, France
  143. Vanderbilt University
  144. Vesigen Therapeutics
  145. Vironova
  146. VivaZome Therapeutics
  147. Xollent Biotech
  148. XOStem

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com